ClinicalTrials.gg
CompletedNCT02577315Updated Nov 30, 2016Results posted

Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

A Phase 1 interventional study of Empagliflozin and Metformin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-30.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Bioequivalence of two 12.5 mg empagliflozin/500 mg metformin fixed dose combination tablets compared to the free combination of empagliflozin 25 mg and metformin 1000 mg in healthy male and female volunteers under fed conditions

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects aged 18 to 45 years and 18.50 to 24.99 kg/m2 by Quetelet
  • Signed prior to admission to the study
  • Subjects must be able to undergo all trial related requests and procedures and follow any trial related restrictions on concomitant medications, diet and life style
  • Subjects must be never-smokers or ex-smokers who stopped smoking prior to enrolment (Visit 1)
  • Male or female subjects using adequate from at least 30 days before the first study drug administration and until 30 days after trial completion

Exclusion criteria

Exclusion criteria:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and any laboratory value outside the reference range
  • Positive results of blood tests for infections (, Syphilis, or C), urine drug screening test and alcohol breath test
  • Any evidence of a concomitant disease judged by the investigator and presence of cardiovascular, respiratory, nervous, endocrine, reproductive, hematopoietic, immune system disorders; gastrointestinal, hepatic, urinary tract, hepatobiliary disorder, mental disturbance
  • Surgery of the gastrointestinal tract that could interfere with kinetics of the study drugs (except appendectomy)
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Relevant chronic or aAcute infections/ acute diseases occurred within 4 weeks before inclusion into the study
  • History of relevant allergy/ (including allergy to the trial medication or its )
  • Regular use of medicinal products less than 2 weeks before drug administration
  • Intake of systemic inhibitors or inductors of microsomal hepatic enzymes in less than 30 days before investigational drug administration
  • Intake of drugs with a long half-life (¿24 hours) within 30 days or less than 10 half-lives of the respective drug prior to administration of trial medication
  • Use of drugs which might reasonably influence the results of the trial based on current knowledge within 14 days prior to drug administration or during the trial
  • Participation in another trial with investigational drug administration within 3 months prior to administration of trial medication
  • Alcohol intake = 10 units of alcohol per week (1 unit of alcohol equals one 50 ml single measure of distilled alcoholic beverages/spirits (ABV 40%), or 0.5 litre of beer (ABV 5%), or 200 ml glass or red wine (ABV 12%) or history of alcohol abuse, narcomania, or other drug abuse.
  • Drug abuse
  • Blood donation (more than 100 mL within 30 days prior to administration of trial medication or intended during the trial)
  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  • Inability to comply with dietary regimen as per protocol and per protocol procedures
  • Subject is assessed by the investigator as unsuitable for inclusion, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
  • Intake of xanthine-containing drinks or foods and alcohol from 72 h before screening and second treatment period
  • Intake of drinks or foods containing grapefruits, Chinese grapefruits, Seville oranges for female subjects:
  • Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after study completion
  • Breast feeding
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Test - Empagliflozin/Metformin

    fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin, oral with 200 mL of water uder fed conditions

    Drug: Empagliflozin · Drug: Metformin

  • Experimental
    Reference - Empagliflozin + Metformin

    free combination of 1 tablet of 25 mg Empagliflozin and 1 tablet of 1000 mg of Metformin, oral with 200 mL of water under fed conditions

    Drug: Empagliflozin · Drug: Metformin

Interventions

  • Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin

  • Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin

  • Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin

  • Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of the Empagliflozin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

    Time frame: PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.

  2. Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of the Metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

    Time frame: PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.

  3. Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)

    Maximum measured concentration of the Empagliflozin in plasma (Cmax). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

    Time frame: PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.

  4. Maximum Measured Concentration of the Metformin in Plasma (Cmax)

    Maximum measured concentration of the Metformin in plasma (Cmax). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

    Time frame: PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.

Secondary outcomes

  1. Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)

    Area under the concentration-time curve of the Empagliflozin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-infinity observed). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

    Time frame: PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.

  2. Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)

    Area under the concentration-time curve of the Metformin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-infinity observed). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

    Time frame: PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.

07

Results

Posted Nov 30, 2016

Participant flow

Actual number of subjects enrolled in fact represents entered / randomized subjects due to the study set up.

Treatment Period 1 (4 Days)
Participant flow — Treatment Period 1 (4 Days)
MilestoneFixed Dose Combination (FDC) / Empagliflozin + MetforminEmpagliflozin + Metformin / Fixed Dose Combination (FDC)
Started1213
Completed1212
Not completed01
Withdrew: Withdrawal by subject01
Washout Period (5 Days)
Participant flow — Washout Period (5 Days)
MilestoneFixed Dose Combination (FDC) / Empagliflozin + MetforminEmpagliflozin + Metformin / Fixed Dose Combination (FDC)
Started1212
Completed1212
Not completed00
Treatment Period 2 (4 Days)
Participant flow — Treatment Period 2 (4 Days)
MilestoneFixed Dose Combination (FDC) / Empagliflozin + MetforminEmpagliflozin + Metformin / Fixed Dose Combination (FDC)
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of the Empagliflozin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

Time frame:
PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.
Reported as:
Geometric mean · nanomol (nmol)* hours (h) / Litre (L)
Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
nanomol (nmol)* hours (h) / Litre (L)Empagliflozin / Metformin (FDC)Empagliflozin + Metformin Free Combination
Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)6147 ± 5.46141 ± 5.4
Statistical analysis
  • Empagliflozin / Metformin (FDC) vs Empagliflozin + Metformin Free Combination · ANOVA · Ratio of geometric means: 100.10 · 90% CI 97.466 to 102.804Relative bioavailability of Empagliflozin was estimated by the ratios of the adjusted geometric means (gMean).
PrimaryArea Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of the Metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

Time frame:
PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.
Reported as:
Geometric mean · nanogram (ng)*h /millilitre (mL)
Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
nanogram (ng)*h /millilitre (mL)Empagliflozin / Metformin (FDC)Empagliflozin + Metformin Free Combination
Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)11912 ± 13.612472 ± 13.6
Statistical analysis
  • Empagliflozin / Metformin (FDC) vs Empagliflozin + Metformin Free Combination · ANOVA · Ratio of geometric means: 95.51 · 90% CI 89.29 to 102.16Relative bioavailability of Metformin was estimated by the ratios of the adjusted geometric means (gMean).
PrimaryMaximum Measured Concentration of the Empagliflozin in Plasma (Cmax)

Maximum measured concentration of the Empagliflozin in plasma (Cmax). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

Time frame:
PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.
Reported as:
Geometric mean · nmol/L
Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)
nmol/LEmpagliflozin / Metformin (FDC)Empagliflozin + Metformin Free Combination
Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)660 ± 10.9642 ± 10.9
Statistical analysis
  • Empagliflozin / Metformin (FDC) vs Empagliflozin + Metformin Free Combination · ANOVA · Ratio of geometric means: 102.71 · 90% CI 97.309 to 108.413Relative bioavailability of Empagliflozin was estimated by the ratios of the adjusted geometric means (gMean).
PrimaryMaximum Measured Concentration of the Metformin in Plasma (Cmax)

Maximum measured concentration of the Metformin in plasma (Cmax). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

Time frame:
PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration of the Metformin in Plasma (Cmax)
ng/mLEmpagliflozin / Metformin (FDC)Empagliflozin + Metformin Free Combination
Maximum Measured Concentration of the Metformin in Plasma (Cmax)1452 ± 11.31437 ± 11.3
Statistical analysis
  • Empagliflozin / Metformin (FDC) vs Empagliflozin + Metformin Free Combination · ANOVA · Ratio of geometric means: 101.07 · 90% CI 95.565 to 106.902Relative bioavailability of Metformin was estimated by the ratios of the adjusted geometric means (gMean).
SecondaryArea Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)

Area under the concentration-time curve of the Empagliflozin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-infinity observed). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

Time frame:
PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)
nmol*h/LEmpagliflozin / Metformin (FDC)Empagliflozin + Metformin Free Combination
Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)6280 ± 5.76261 ± 5.7
Statistical analysis
  • Empagliflozin / Metformin (FDC) vs Empagliflozin + Metformin Free Combination · ANOVA · Ratio of geometric means: 100.30 · 90% CI 97.532 to 103.149Relative bioavailability of Empagliflozin was estimated by the ratios of the adjusted geometric means (gMean).
SecondaryArea Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)

Area under the concentration-time curve of the Metformin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-infinity observed). Geometric means (gMeans) represent adjusted gMeans and geometric coefficient of variation (gCV) reflects the intra-individual gCV (%) from the mixed model analysis.

Time frame:
PK plasma samples were taken at: 2 hours (h) before drug administration and 20 minutes, 40 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)
ng*h/mLEmpagliflozin / Metformin (FDC)Empagliflozin + Metformin Free Combination
Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)12428 ± 24.813285 ± 24.8
Statistical analysis
  • Empagliflozin / Metformin (FDC) vs Empagliflozin + Metformin Free Combination · ANOVA · Ratio of geometric means: 93.55 · 90% CI 82.86 to 105.61Relative bioavailability of Metformin was estimated by the ratios of the adjusted geometric means (gMean).

Adverse events

Collected over From first drug administration until 14 days after the last drug administration, up to 27 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empagliflozin / Metformin (FDC)—0/24 (0%)0/24 (0%)
Empagliflozin + Metformin Free Combination—0/25 (0%)0/25 (0%)

Baseline characteristics

Treated set (TS): all subjects who were randomised to study medication and were documented to have received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Fixed Dose Combination (FDC) / Empagliflozin + MetforminEmpagliflozin + Metformin / Fixed Dose Combination (FDC)Total
Mean24.7 ± 3.630.4 ± 7.827.6 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)Fixed Dose Combination (FDC) / Empagliflozin + MetforminEmpagliflozin + Metformin / Fixed Dose Combination (FDC)Total
Female4913
Male8412
08

Study locations

1 site
  • 1276.27.001 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2015
First posted
Oct 16, 2015
Start
Sep 2015
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
Nov 30, 2016
Last update
Nov 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02577315
Responsible party
Sponsor
First posted
Oct 16, 2015
Start date
Sep 2015
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Nov 30, 2016
Last update
Nov 30, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin

Start the discussion